The effectiveness of intralesional
sclerotherapy of
lymphangiomas and
ranulas with
OK-432 (
Picibanil) has been proved in several clinical studies. The aim of our study was to review the effectiveness of
sclerotherapy of benign cervical
cysts with
Picibanil as an alternative method to surgical excision. Between March 2002 and March 2006, a prospective observational study was carried out to assess the effects of
Picibanil on cervical
cysts. Between 2002 and 2006 we treated 14 patients having cervical
cysts through intralesional application of
Picibanil with a dose of 0.01 mg/ml. So far we used
Picibanil with 13 patients achieving a high success rate. In eight cases we observed, both clinically and ultrasonographically, a nearly complete regression, and a complete regression of the
cysts in three cases. In two cases the
cysts atrophied. In these cases only residual findings could be observed. In one case we extirpated the remaining
cyst. If there is no clear reaction of the
cyst to the treatment, an excision is indicated 6 weeks after the
injections to gain meaningful histological examination. No significant complication after
sclerotherapy with
Picibanil was observed. According to our results the application of
OK-432 (
Picibanil) is a safe and effective primary method for
sclerotherapy of benign cervical
cysts which can replace surgical extirpation in special cases. However, the risk of malign diseases has to be excluded before the commencement of the
Picibanil treatment.